Article - 29 May 2024 Cell and gene therapy answers: Addressing challenges and de-risking clinical oncology development
Article - 13 September 2023 Labcorp expanding bioanalytical service offering in the Asia-Pacific region with an integrated laboratory in Singapore
Press Release - 16 May 2023 Labcorp and BML announce expansion of clinical laboratory testing capabilities in Japan
Poster - 2 June 2024 Quantification of the monoclonal antibody pembrolizumab in human blood collected via volumetric adsorptive microsampling (VAMS) technology and utilizing LC-MS/MS detection Read Moreabout Quantification of the monoclonal antibody pembrolizumab in human blood collected via volumetric adsorptive microsampling (VAMS) technology and utilizing LC-MS/MS detection
Poster - 19 May 2024 Formulation development and characterization of a Marburg self-amplifying mRNA-lipid nanoparticle vaccine with toll-like receptor-7 agonists Read Moreabout Formulation development and characterization of a Marburg self-amplifying mRNA-lipid nanoparticle vaccine with toll-like receptor-7 agonists
Poster - 5 May 2024 Development and validation of a fit-for-purpose biomarker LC-MS/MS assay measuring 15 plasma bile acids Read Moreabout Development and validation of a fit-for-purpose biomarker LC-MS/MS assay measuring 15 plasma bile acids
Poster - 4 May 2024 Validation of a flow cytometry-based basophil degranulation assay for use in multi-centric clinical trials Read Moreabout Validation of a flow cytometry-based basophil degranulation assay for use in multi-centric clinical trials
Poster - 4 October 2023 Rational selection of Toll-like receptor agonists (TLR) for the development of Marburg vaccine formulation Read Moreabout Rational selection of Toll-like receptor agonists (TLR) for the development of Marburg vaccine formulation
Poster - 4 October 2023 Second generation mRNA Marburg vaccine: Formulation development of mRNA-lipid nanoparticles with TLR9 agonist CpG oligonucleotide adjuvant Read Moreabout Second generation mRNA Marburg vaccine: Formulation development of mRNA-lipid nanoparticles with TLR9 agonist CpG oligonucleotide adjuvant
Manuscript - 1 September 2020 A customized scaffolds approach for the detection and phasing of complex variants by next-generation sequencing Read Moreabout A customized scaffolds approach for the detection and phasing of complex variants by next-generation sequencing
Aaron Ledvina, PhD Senior Scientific Support Specialist, LC-MS Bioanalytical Services Read Moreabout Aaron Ledvina, PhD
Colin Guy, PhD Senior Manager Assay Development, Method Development & Validation Read Moreabout Colin Guy, PhD
Daniel Sikkema, PhD Executive Director, Global Immunochemistry Bioanalytical Services Read Moreabout Daniel Sikkema, PhD
Eric Thomas, PhD Global Director of Method Development & Validation, LC-MS Bioanalytical Services Read Moreabout Eric Thomas, PhD
Graeme Evans Global Director, Method Development & Validation Immunochemistry Read Moreabout Graeme Evans
Henry Fisher, PhD Assay Development Scientist, Method Development & Validation Read Moreabout Henry Fisher, PhD
James Tunaley, PhD Study Director & Scientist, Molecular Bioanalysis Read Moreabout James Tunaley, PhD
Jill Uhlenkamp, PhD Senior Method Development Manager, Immunochemistry Read Moreabout Jill Uhlenkamp, PhD
Lee Goodwin, PhD Executive Director, Global LC-MS Bioanalytical Services Read Moreabout Lee Goodwin, PhD
Leonard Bell, PhD Lead Assay Development Scientist, Method Development & Validation Read Moreabout Leonard Bell, PhD
Rachel Smith, PhD Assay Development Scientist, Method Development & Validation Read Moreabout Rachel Smith, PhD
Stephanie Cape, PhD Head of Research and Development and Delivery, Scientific Affairs Read Moreabout Stephanie Cape, PhD